DELIVRA HEALTH BRANDS INC (DHB.CA) Stock Fundamental Analysis

Canada • TSX Venture Exchange • TSX-V:DHB • CA24703H2019

0.18 CAD
0 (0%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall DHB gets a fundamental rating of 3 out of 10. We evaluated DHB against 33 industry peers in the Pharmaceuticals industry. While DHB seems to be doing ok healthwise, there are quite some concerns on its profitability. DHB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year DHB has reported negative net income.
  • In the past year DHB has reported a negative cash flow from operations.
  • DHB had negative earnings in 4 of the past 5 years.
  • In the past 5 years DHB reported 4 times negative operating cash flow.
DHB.CA Yearly Net Income VS EBIT VS OCF VS FCFDHB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.86%, DHB is in line with its industry, outperforming 51.52% of the companies in the same industry.
  • With a Return On Equity value of -18.62%, DHB perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
ROA -8.86%
ROE -18.62%
ROIC N/A
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
DHB.CA Yearly ROA, ROE, ROICDHB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • DHB's Gross Margin of 49.16% is fine compared to the rest of the industry. DHB outperforms 66.67% of its industry peers.
  • In the last couple of years the Gross Margin of DHB has grown nicely.
  • The Profit Margin and Operating Margin are not available for DHB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
DHB.CA Yearly Profit, Operating, Gross MarginsDHB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DHB remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for DHB has been increased compared to 5 years ago.
  • The debt/assets ratio for DHB is higher compared to a year ago.
DHB.CA Yearly Shares OutstandingDHB.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
DHB.CA Yearly Total Debt VS Total AssetsDHB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • DHB has an Altman-Z score of -19.41. This is a bad value and indicates that DHB is not financially healthy and even has some risk of bankruptcy.
  • DHB has a Altman-Z score of -19.41. This is amonst the worse of the industry: DHB underperforms 87.88% of its industry peers.
  • DHB has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
  • DHB has a Debt to Equity ratio (0.43) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -19.41
ROIC/WACCN/A
WACC7.36%
DHB.CA Yearly LT Debt VS Equity VS FCFDHB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • DHB has a Current Ratio of 3.14. This indicates that DHB is financially healthy and has no problem in meeting its short term obligations.
  • DHB's Current ratio of 3.14 is fine compared to the rest of the industry. DHB outperforms 78.79% of its industry peers.
  • A Quick Ratio of 2.35 indicates that DHB has no problem at all paying its short term obligations.
  • DHB has a Quick ratio of 2.35. This is amongst the best in the industry. DHB outperforms 87.88% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.35
DHB.CA Yearly Current Assets VS Current LiabilitesDHB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • DHB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -560.71%.
  • The Revenue has grown by 13.01% in the past year. This is quite good.
  • DHB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.44% yearly.
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 49.00% on average over the next years. This is a very strong growth
  • DHB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.79% yearly.
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DHB.CA Yearly Revenue VS EstimatesDHB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
DHB.CA Yearly EPS VS EstimatesDHB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DHB. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 15.89, the valuation of DHB can be described as correct.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DHB indicates a somewhat cheap valuation: DHB is cheaper than 72.73% of the companies listed in the same industry.
  • DHB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 15.89
DHB.CA Price Earnings VS Forward Price EarningsDHB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DHB is valued a bit cheaper than 60.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.78
DHB.CA Per share dataDHB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • DHB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • DHB's earnings are expected to grow with 49.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DHB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DELIVRA HEALTH BRANDS INC

TSX-V:DHB (2/6/2026, 7:00:00 PM)

0.18

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)02-25
Inst Owners1.86%
Inst Owner ChangeN/A
Ins Owners13.18%
Ins Owner ChangeN/A
Market Cap5.63M
Revenue(TTM)13.41M
Net Income(TTM)-806.00K
Analysts84.44
Price Target0.73 (305.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.89
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.3
EV/EBITDA 10.78
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY6.29%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.43
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.86%
ROE -18.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.16%
FCFM N/A
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
F-Score3
Asset Turnover1.48
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA 4.42
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 2.35
Altman-Z -19.41
F-Score3
WACC7.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year212.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.19%
OCF growth 3YN/A
OCF growth 5YN/A

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DHB.CA.


What is the valuation status for DHB stock?

ChartMill assigns a valuation rating of 4 / 10 to DELIVRA HEALTH BRANDS INC (DHB.CA). This can be considered as Fairly Valued.


What is the profitability of DHB stock?

DELIVRA HEALTH BRANDS INC (DHB.CA) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for DHB stock?

The Earnings per Share (EPS) of DELIVRA HEALTH BRANDS INC (DHB.CA) is expected to grow by 80% in the next year.